Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
American Association of Cancer Research (AACR) to hold virtual meeting » 05:55
06/24/20
06/24
05:55
06/24/20
05:55
A

Agilent

$89.36 /

+0.81 (+0.91%)

, ABBV

AbbVie

$97.28 /

+0.03 (+0.03%)

, ADPT

Adaptive Biotechnologies

$46.95 /

+1.04 (+2.27%)

, AZN

AstraZeneca

$54.24 /

+0.8 (+1.50%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BGNE

BeiGene

$187.74 /

+4.42 (+2.41%)

, BMY

Bristol-Myers

$58.41 /

+0.85 (+1.48%)

, BNTX

BioNTech

$52.80 /

-4.64 (-8.08%)

, CRL

Charles River

$175.05 /

-0.12 (-0.07%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, GH

Guardant Health

$83.33 /

+0.26 (+0.31%)

, GILD

Gilead

$75.01 /

-0.61 (-0.81%)

, PFE

Pfizer

$32.78 /

-0.33 (-1.00%)

, NVS

Novartis

$90.49 /

-0.09 (-0.10%)

, NVCR

Novocure

$62.71 /

-0.31 (-0.49%)

, NTRA

Natera

$46.65 /

+0.36 (+0.78%)

, SNY

Sanofi

$52.49 /

-0.06 (-0.11%)

, RUBY

Rubius Therapeutics

$6.52 /

-0.02 (-0.31%)

, NEO

NeoGenomics

$29.05 /

+0.49 (+1.72%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RCUS

Arcus Biosciences

$25.06 /

-0.75 (-2.91%)

, QGEN

Qiagen

$42.87 /

+0.31 (+0.73%)

, LLY

Eli Lilly

$159.35 /

-1.06 (-0.66%)

, PKI

PerkinElmer

$99.11 /

+1.08 (+1.10%)

, GSK

GlaxoSmithKline

$41.60 /

+0.37 (+0.90%)

, ILMN

Illumina

$367.22 /

+7.02 (+1.95%)

AACR Annual Meeting 2020:…

AACR Annual Meeting 2020: Virtual Meeting II will be held on June 22-24. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVCR Novocure
$62.71 /

-0.31 (-0.49%)

NTRA Natera
$46.65 /

+0.36 (+0.78%)

NEO NeoGenomics
$29.05 /

+0.49 (+1.72%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

GH Guardant Health
$83.33 /

+0.26 (+0.31%)

ESALY Eisai
$0.00 /

+ (+0.00%)

CRL Charles River
$175.05 /

-0.12 (-0.07%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

A Agilent
$89.36 /

+0.81 (+0.91%)

05/22/20 Cowen
Agilent price target raised to $95 from $80 at Cowen
03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

06/23/20
Fly Intel: Top five analyst upgrades
06/23/20 Atlantic Equities
AbbVie upgraded to Overweight from Neutral at Atlantic Equities
06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/23/20 Berenberg
Bayer price target raised to EUR 86 from EUR 82 at Berenberg
06/17/20 Deutsche Bank
Bayer named short-term buy idea at Deutsche Bank
06/16/20 Commerzbank
Bayer upgraded to Buy from Hold at Commerzbank
06/08/20 Monness Crespi
Corteva downgraded to Sell from Neutral at Monness Crespi
BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

06/03/20 Piper Sandler
BeiGene earned 'meaningful' approvals for Brukinsa in China, says Piper Sandler
03/25/20 Piper Sandler
BeiGene Abraxane issue could take months to resolve, says Piper Sandler
03/13/20 Macquarie
BeiGene upgraded to Neutral from Underperform at Macquarie
03/03/20 Maxim
BeiGene price target lowered to $190 from $210 at Maxim
BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/13/20 H.C. Wainwright
BioNTech price target raised to $48 from $30 at H.C. Wainwright
CRL Charles River
$175.05 /

-0.12 (-0.07%)

05/26/20 Argus
Charles River price target raised to $190 from $150 at Argus
05/13/20 UBS
Charles River upgraded to Buy from Neutral at UBS
05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
GH Guardant Health
$83.33 /

+0.26 (+0.31%)

06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
05/08/20 Citi
Guardant Health price target raised to $110 from $100 at Citi
GILD Gilead
$75.01 /

-0.61 (-0.81%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/08/20 JPMorgan
JPMorgan's Kasimov gives 'GileastraZeneca' low odds of happening
06/08/20 Jefferies
Jefferies' Welford questions benefit to AstraZeneca of merger with Gilead
PFE Pfizer
$32.78 /

-0.33 (-1.00%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
NVS Novartis
$90.49 /

-0.09 (-0.10%)

06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
06/03/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful
NVCR Novocure
$62.71 /

-0.31 (-0.49%)

05/20/20 Piper Sandler
Novocure remains top idea in oncology equipment at Piper Sandler
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
NTRA Natera
$46.65 /

+0.36 (+0.78%)

06/22/20 Piper Sandler
Invitae deal for ArcherDx presents little threat to Natera, says Piper Sandler
06/09/20 Piper Sandler
Natera transferred with an Overweight at Piper Sandler
05/14/20 Piper Sandler
Natera price target raised to $56 from $49 at Piper Sandler
05/07/20 JPMorgan
Natera upgraded to Overweight on 'de-risked' story at JPMorgan
SNY Sanofi
$52.49 /

-0.06 (-0.11%)

06/23/20 Jefferies
Translate Bio price target raised to $29 from $17 at Jefferies
06/23/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
03/13/20 Morgan Stanley
Rubius Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
NEO NeoGenomics
$29.05 /

+0.49 (+1.72%)

04/21/20 Stephens
NeoGenomics resumed with an Overweight at Stephens
03/17/20 Needham
Needham adds NeoGenomics to Conviction List, boosts target to $33
03/02/20 Craig-Hallum
NeoGenomics resumed with a Buy at Craig-Hallum
03/02/20 Raymond James
NeoGenomics price target raised to $32 from $28 at Raymond James
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

04/27/20 Cleveland Research
PerkinElmer estimates lowered further on headwinds at Cleveland Research
01/07/20 Wells Fargo
PerkinElmer initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
PerkinElmer initiated with a Neutral at Citi
01/02/20 Evercore ISI
PerkinElmer upgraded to Outperform from In Line at Evercore ISI
GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
ILMN Illumina
$367.22 /

+7.02 (+1.95%)

05/21/20 Argus
Illumina price target raised to $380 from $340 at Argus
05/01/20 Piper Sandler
Illumina price target lowered to $356 from $370 at Piper Sandler
05/01/20 Cowen
Illumina price target raised to $320 from $275 at Cowen
04/24/20 Citi
Illumina downgraded to Neutral from Buy on valuation at Citi
SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVCR Novocure
$62.71 /

-0.31 (-0.49%)

NTRA Natera
$46.65 /

+0.36 (+0.78%)

NEO NeoGenomics
$29.05 /

+0.49 (+1.72%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

GH Guardant Health
$83.33 /

+0.26 (+0.31%)

CRL Charles River
$175.05 /

-0.12 (-0.07%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RUBY Rubius Therapeutics
$6.52 /

-0.02 (-0.31%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PKI PerkinElmer
$99.11 /

+1.08 (+1.10%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVCR Novocure
$62.71 /

-0.31 (-0.49%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

GH Guardant Health
$83.33 /

+0.26 (+0.31%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

BGNE BeiGene
$187.74 /

+4.42 (+2.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ADPT Adaptive Biotechnologies
$46.95 /

+1.04 (+2.27%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

SNY Sanofi
$52.49 /

-0.06 (-0.11%)

RCUS Arcus Biosciences
$25.06 /

-0.75 (-2.91%)

QGEN Qiagen
$42.87 /

+0.31 (+0.73%)

PFE Pfizer
$32.78 /

-0.33 (-1.00%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

LLY Eli Lilly
$159.35 /

-1.06 (-0.66%)

ILMN Illumina
$367.22 /

+7.02 (+1.95%)

GSK GlaxoSmithKline
$41.60 /

+0.37 (+0.90%)

GILD Gilead
$75.01 /

-0.61 (-0.81%)

BNTX BioNTech
$52.80 /

-4.64 (-8.08%)

BMY Bristol-Myers
$58.41 /

+0.85 (+1.48%)

AZN AstraZeneca
$54.24 /

+0.8 (+1.50%)

ABBV AbbVie
$97.28 /

+0.03 (+0.03%)

A Agilent
$89.36 /

+0.81 (+0.91%)

Conference/Events
American Association of Cancer Research (AACR) to hold virtual meeting » 04:55
06/23/20
06/23
04:55
06/23/20
04:55
A

Agilent

$88.55 /

-0.27 (-0.30%)

, ABBV

AbbVie

$97.25 /

+0.53 (+0.55%)

, ADPT

Adaptive Biotechnologies

$45.91 /

+1.24 (+2.78%)

, AZN

AstraZeneca

$53.44 /

+0.39 (+0.74%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BGNE

BeiGene

$183.32 /

+0.75 (+0.41%)

, BMY

Bristol-Myers

$57.56 /

+1.22 (+2.17%)

, BNTX

BioNTech

$57.44 /

+6.02 (+11.71%)

, CRL

Charles River

$175.17 /

-3.21 (-1.80%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, GH

Guardant Health

$83.07 /

+4.14 (+5.25%)

, GILD

Gilead

$75.62 /

-1.61 (-2.08%)

, PFE

Pfizer

$33.11 /

-0.32 (-0.96%)

, NVS

Novartis

$90.58 /

-0.55 (-0.60%)

, NVCR

Novocure

$63.02 /

-0.33 (-0.52%)

, NTRA

Natera

$46.29 /

-0.16 (-0.34%)

, SNY

Sanofi

$52.55 /

+0.25 (+0.48%)

, RUBY

Rubius Therapeutics

$6.54 /

+0.07 (+1.08%)

, NEO

NeoGenomics

$28.56 /

+0.17 (+0.60%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RCUS

Arcus Biosciences

$25.81 /

-0.23 (-0.88%)

, QGEN

Qiagen

$42.56 /

-0.03 (-0.07%)

, LLY

Eli Lilly

$160.41 /

+0.51 (+0.32%)

, PKI

PerkinElmer

$98.03 /

-0.48 (-0.49%)

, GSK

GlaxoSmithKline

$41.23 /

+0.11 (+0.27%)

, ILMN

Illumina

$360.20 /

-10.23 (-2.76%)

AACR Annual Meeting 2020:…

AACR Annual Meeting 2020: Virtual Meeting II will be held on June 22-24. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RUBY Rubius Therapeutics
$6.54 /

+0.07 (+1.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

NVCR Novocure
$63.02 /

-0.33 (-0.52%)

NTRA Natera
$46.29 /

-0.16 (-0.34%)

NEO NeoGenomics
$28.56 /

+0.17 (+0.60%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

ILMN Illumina
$360.20 /

-10.23 (-2.76%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

GH Guardant Health
$83.07 /

+4.14 (+5.25%)

ESALY Eisai
$0.00 /

+ (+0.00%)

CRL Charles River
$175.17 /

-3.21 (-1.80%)

BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

BGNE BeiGene
$183.32 /

+0.75 (+0.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$45.91 /

+1.24 (+2.78%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

A Agilent
$88.55 /

-0.27 (-0.30%)

05/22/20 Cowen
Agilent price target raised to $95 from $80 at Cowen
03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/18/20 Wedbush
Biohaven Pharmaceutical price target raised to $94 from $74 at Wedbush
ADPT Adaptive Biotechnologies
$45.91 /

+1.24 (+2.78%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
06/08/20 JPMorgan
JPMorgan's Kasimov gives 'GileastraZeneca' low odds of happening
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/17/20 Deutsche Bank
Bayer named short-term buy idea at Deutsche Bank
06/16/20 Commerzbank
Bayer upgraded to Buy from Hold at Commerzbank
06/08/20 Monness Crespi
Corteva downgraded to Sell from Neutral at Monness Crespi
06/04/20 BMO Capital
Dicamba ruling likely a mid-term positive for Corteva, says BMO Capital
BGNE BeiGene
$183.32 /

+0.75 (+0.41%)

06/03/20 Piper Sandler
BeiGene earned 'meaningful' approvals for Brukinsa in China, says Piper Sandler
03/25/20 Piper Sandler
BeiGene Abraxane issue could take months to resolve, says Piper Sandler
03/13/20 Macquarie
BeiGene upgraded to Neutral from Underperform at Macquarie
03/03/20 Maxim
BeiGene price target lowered to $190 from $210 at Maxim
BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/13/20 H.C. Wainwright
BioNTech price target raised to $48 from $30 at H.C. Wainwright
CRL Charles River
$175.17 /

-3.21 (-1.80%)

05/26/20 Argus
Charles River price target raised to $190 from $150 at Argus
05/13/20 UBS
Charles River upgraded to Buy from Neutral at UBS
05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
GH Guardant Health
$83.07 /

+4.14 (+5.25%)

06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
05/08/20 Citi
Guardant Health price target raised to $110 from $100 at Citi
GILD Gilead
$75.62 /

-1.61 (-2.08%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/08/20 Jefferies
Jefferies' Welford questions benefit to AstraZeneca of merger with Gilead
PFE Pfizer
$33.11 /

-0.32 (-0.96%)

06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
06/16/20 SVB Leerink
Pfizer initiated with a Market Perform at SVB Leerink
06/09/20 Piper Sandler
Opko Health price target raised to $4 from $3 at Piper Sandler
NVS Novartis
$90.58 /

-0.55 (-0.60%)

06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
06/03/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful
NVCR Novocure
$63.02 /

-0.33 (-0.52%)

05/20/20 Piper Sandler
Novocure remains top idea in oncology equipment at Piper Sandler
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
NTRA Natera
$46.29 /

-0.16 (-0.34%)

06/22/20 Piper Sandler
Invitae deal for ArcherDx presents little threat to Natera, says Piper Sandler
06/09/20 Piper Sandler
Natera transferred with an Overweight at Piper Sandler
05/14/20 Piper Sandler
Natera price target raised to $56 from $49 at Piper Sandler
05/07/20 JPMorgan
Natera upgraded to Overweight on 'de-risked' story at JPMorgan
SNY Sanofi
$52.55 /

+0.25 (+0.48%)

06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/12/20 Jefferies
Regeneron price target raised to $691 from $657 at Jefferies
06/10/20 Morgan Stanley
Denali shares to be under pressure after DNL747 decision, says Morgan Stanley
06/09/20 Morgan Stanley
Sanofi price target raised to EUR 107 from EUR 101 at Morgan Stanley
RUBY Rubius Therapeutics
$6.54 /

+0.07 (+1.08%)

03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
03/13/20 Morgan Stanley
Rubius Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
NEO NeoGenomics
$28.56 /

+0.17 (+0.60%)

04/21/20 Stephens
NeoGenomics resumed with an Overweight at Stephens
03/17/20 Needham
Needham adds NeoGenomics to Conviction List, boosts target to $33
03/02/20 Craig-Hallum
NeoGenomics resumed with a Buy at Craig-Hallum
03/02/20 Raymond James
NeoGenomics price target raised to $32 from $28 at Raymond James
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
06/16/20 Guggenheim
Eli Lilly upgraded to Buy from Neutral at Guggenheim
PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

04/27/20 Cleveland Research
PerkinElmer estimates lowered further on headwinds at Cleveland Research
01/07/20 Wells Fargo
PerkinElmer initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
PerkinElmer initiated with a Neutral at Citi
01/02/20 Evercore ISI
PerkinElmer upgraded to Outperform from In Line at Evercore ISI
GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
ILMN Illumina
$360.20 /

-10.23 (-2.76%)

05/21/20 Argus
Illumina price target raised to $380 from $340 at Argus
05/01/20 Piper Sandler
Illumina price target lowered to $356 from $370 at Piper Sandler
05/01/20 Cowen
Illumina price target raised to $320 from $275 at Cowen
04/24/20 Citi
Illumina downgraded to Neutral from Buy on valuation at Citi
SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RUBY Rubius Therapeutics
$6.54 /

+0.07 (+1.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

NVCR Novocure
$63.02 /

-0.33 (-0.52%)

NTRA Natera
$46.29 /

-0.16 (-0.34%)

NEO NeoGenomics
$28.56 /

+0.17 (+0.60%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

ILMN Illumina
$360.20 /

-10.23 (-2.76%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

GH Guardant Health
$83.07 /

+4.14 (+5.25%)

CRL Charles River
$175.17 /

-3.21 (-1.80%)

BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

BGNE BeiGene
$183.32 /

+0.75 (+0.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$45.91 /

+1.24 (+2.78%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RUBY Rubius Therapeutics
$6.54 /

+0.07 (+1.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PKI PerkinElmer
$98.03 /

-0.48 (-0.49%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

NVCR Novocure
$63.02 /

-0.33 (-0.52%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

ILMN Illumina
$360.20 /

-10.23 (-2.76%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

GH Guardant Health
$83.07 /

+4.14 (+5.25%)

BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

BGNE BeiGene
$183.32 /

+0.75 (+0.41%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$45.91 /

+1.24 (+2.78%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

SNY Sanofi
$52.55 /

+0.25 (+0.48%)

RCUS Arcus Biosciences
$25.81 /

-0.23 (-0.88%)

QGEN Qiagen
$42.56 /

-0.03 (-0.07%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

NVS Novartis
$90.58 /

-0.55 (-0.60%)

LLY Eli Lilly
$160.41 /

+0.51 (+0.32%)

ILMN Illumina
$360.20 /

-10.23 (-2.76%)

GSK GlaxoSmithKline
$41.23 /

+0.11 (+0.27%)

GILD Gilead
$75.62 /

-1.61 (-2.08%)

BNTX BioNTech
$57.44 /

+6.02 (+11.71%)

BMY Bristol-Myers
$57.56 /

+1.22 (+2.17%)

AZN AstraZeneca
$53.44 /

+0.39 (+0.74%)

ABBV AbbVie
$97.25 /

+0.53 (+0.55%)

A Agilent
$88.55 /

-0.27 (-0.30%)

Conference/Events
American Association of Cancer Research (AACR) to hold virtual meeting » 08:42
06/22/20
06/22
08:42
06/22/20
08:42
A

Agilent

$88.82 /

+0.6 (+0.68%)

, ABBV

AbbVie

$96.72 /

+0.45 (+0.47%)

, ADPT

Adaptive Biotechnologies

$44.67 /

+0.14 (+0.31%)

, AZN

AstraZeneca

$53.05 /

+0.39 (+0.74%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BGNE

BeiGene

$182.57 /

+5.09 (+2.87%)

, BMY

Bristol-Myers

$56.34 /

+0.35 (+0.63%)

, BNTX

BioNTech

$51.42 /

+0.48 (+0.94%)

, CRL

Charles River

$178.38 /

-0.31 (-0.17%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, GH

Guardant Health

$78.93 /

-0.62 (-0.78%)

, GILD

Gilead

$77.23 /

+3.18 (+4.29%)

, PFE

Pfizer

$33.43 /

+0.2 (+0.60%)

, NVS

Novartis

$91.13 /

+1.47 (+1.64%)

, NVCR

Novocure

$63.35 /

+0.83 (+1.33%)

, NTRA

Natera

$46.45 /

+0.43 (+0.93%)

, SNY

Sanofi

$52.30 /

+0.84 (+1.63%)

, RUBY

Rubius Therapeutics

$6.47 /

+0.09 (+1.41%)

, NEO

NeoGenomics

$28.39 /

+0.145 (+0.51%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RCUS

Arcus Biosciences

$26.04 /

-1.46 (-5.31%)

, QGEN

Qiagen

$42.59 /

+0.17 (+0.40%)

, LLY

Eli Lilly

$159.90 /

-1.14 (-0.71%)

, PKI

PerkinElmer

$98.51 /

+0.565 (+0.58%)

, GSK

GlaxoSmithKline

$41.12 /

+0.18 (+0.44%)

, ILMN

Illumina

$370.43 /

+8.18 (+2.26%)

AACR Annual Meeting 2020:…

AACR Annual Meeting 2020: Virtual Meeting II will be held on June 22-24. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RUBY Rubius Therapeutics
$6.47 /

+0.09 (+1.41%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

NVCR Novocure
$63.35 /

+0.83 (+1.33%)

NTRA Natera
$46.45 /

+0.43 (+0.93%)

NEO NeoGenomics
$28.39 /

+0.145 (+0.51%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

ILMN Illumina
$370.43 /

+8.18 (+2.26%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

GH Guardant Health
$78.93 /

-0.62 (-0.78%)

ESALY Eisai
$0.00 /

+ (+0.00%)

CRL Charles River
$178.38 /

-0.31 (-0.17%)

BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$44.67 /

+0.14 (+0.31%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

A Agilent
$88.82 /

+0.6 (+0.68%)

05/22/20 Cowen
Agilent price target raised to $95 from $80 at Cowen
03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/18/20 Wedbush
Biohaven Pharmaceutical price target raised to $94 from $74 at Wedbush
ADPT Adaptive Biotechnologies
$44.67 /

+0.14 (+0.31%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
06/08/20 JPMorgan
JPMorgan's Kasimov gives 'GileastraZeneca' low odds of happening
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/17/20 Deutsche Bank
Bayer named short-term buy idea at Deutsche Bank
06/16/20 Commerzbank
Bayer upgraded to Buy from Hold at Commerzbank
06/08/20 Monness Crespi
Corteva downgraded to Sell from Neutral at Monness Crespi
06/04/20 BMO Capital
Dicamba ruling likely a mid-term positive for Corteva, says BMO Capital
BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

06/03/20 Piper Sandler
BeiGene earned 'meaningful' approvals for Brukinsa in China, says Piper Sandler
03/25/20 Piper Sandler
BeiGene Abraxane issue could take months to resolve, says Piper Sandler
03/13/20 Macquarie
BeiGene upgraded to Neutral from Underperform at Macquarie
03/03/20 Maxim
BeiGene price target lowered to $190 from $210 at Maxim
BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
06/02/20 Oppenheimer
Ayala Pharmaceuticals initiated with an Outperform at Oppenheimer
BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/13/20 H.C. Wainwright
BioNTech price target raised to $48 from $30 at H.C. Wainwright
CRL Charles River
$178.38 /

-0.31 (-0.17%)

05/26/20 Argus
Charles River price target raised to $190 from $150 at Argus
05/13/20 UBS
Charles River upgraded to Buy from Neutral at UBS
05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
GH Guardant Health
$78.93 /

-0.62 (-0.78%)

06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
05/08/20 Citi
Guardant Health price target raised to $110 from $100 at Citi
GILD Gilead
$77.23 /

+3.18 (+4.29%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/08/20 Jefferies
Jefferies' Welford questions benefit to AstraZeneca of merger with Gilead
PFE Pfizer
$33.43 /

+0.2 (+0.60%)

06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
06/16/20 SVB Leerink
Pfizer initiated with a Market Perform at SVB Leerink
06/09/20 Piper Sandler
Opko Health price target raised to $4 from $3 at Piper Sandler
06/08/20 Piper Sandler
Opko Health, Pfizer data show IGF-1 normal at ENDO, says Piper Sandler
NVS Novartis
$91.13 /

+1.47 (+1.64%)

06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
06/03/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Genmab, says ofatumumab delay not impactful
NVCR Novocure
$63.35 /

+0.83 (+1.33%)

05/20/20 Piper Sandler
Novocure remains top idea in oncology equipment at Piper Sandler
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
NTRA Natera
$46.45 /

+0.43 (+0.93%)

06/09/20 Piper Sandler
Natera transferred with an Overweight at Piper Sandler
05/14/20 Piper Sandler
Natera price target raised to $56 from $49 at Piper Sandler
05/07/20 JPMorgan
Natera upgraded to Overweight on 'de-risked' story at JPMorgan
05/07/20 JPMorgan
Natera upgraded to Overweight from Neutral at JPMorgan
SNY Sanofi
$52.30 /

+0.84 (+1.63%)

06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/12/20 Jefferies
Regeneron price target raised to $691 from $657 at Jefferies
06/10/20 Morgan Stanley
Denali shares to be under pressure after DNL747 decision, says Morgan Stanley
06/09/20 Morgan Stanley
Sanofi price target raised to EUR 107 from EUR 101 at Morgan Stanley
RUBY Rubius Therapeutics
$6.47 /

+0.09 (+1.41%)

03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
03/13/20 Morgan Stanley
Rubius Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
NEO NeoGenomics
$28.39 /

+0.145 (+0.51%)

04/21/20 Stephens
NeoGenomics resumed with an Overweight at Stephens
03/17/20 Needham
Needham adds NeoGenomics to Conviction List, boosts target to $33
03/02/20 Craig-Hallum
NeoGenomics resumed with a Buy at Craig-Hallum
03/02/20 Raymond James
NeoGenomics price target raised to $32 from $28 at Raymond James
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
06/16/20 Guggenheim
Eli Lilly upgraded to Buy from Neutral at Guggenheim
PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

04/27/20 Cleveland Research
PerkinElmer estimates lowered further on headwinds at Cleveland Research
01/07/20 Wells Fargo
PerkinElmer initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
PerkinElmer initiated with a Neutral at Citi
01/02/20 Evercore ISI
PerkinElmer upgraded to Outperform from In Line at Evercore ISI
GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
ILMN Illumina
$370.43 /

+8.18 (+2.26%)

05/21/20 Argus
Illumina price target raised to $380 from $340 at Argus
05/01/20 Piper Sandler
Illumina price target lowered to $356 from $370 at Piper Sandler
05/01/20 Cowen
Illumina price target raised to $320 from $275 at Cowen
04/24/20 Citi
Illumina downgraded to Neutral from Buy on valuation at Citi
SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RUBY Rubius Therapeutics
$6.47 /

+0.09 (+1.41%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

NVCR Novocure
$63.35 /

+0.83 (+1.33%)

NTRA Natera
$46.45 /

+0.43 (+0.93%)

NEO NeoGenomics
$28.39 /

+0.145 (+0.51%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

ILMN Illumina
$370.43 /

+8.18 (+2.26%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

GH Guardant Health
$78.93 /

-0.62 (-0.78%)

CRL Charles River
$178.38 /

-0.31 (-0.17%)

BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$44.67 /

+0.14 (+0.31%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RUBY Rubius Therapeutics
$6.47 /

+0.09 (+1.41%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PKI PerkinElmer
$98.51 /

+0.565 (+0.58%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

NVCR Novocure
$63.35 /

+0.83 (+1.33%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

ILMN Illumina
$370.43 /

+8.18 (+2.26%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

GH Guardant Health
$78.93 /

-0.62 (-0.78%)

BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

BGNE BeiGene
$182.57 /

+5.09 (+2.87%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ADPT Adaptive Biotechnologies
$44.67 /

+0.14 (+0.31%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

SNY Sanofi
$52.30 /

+0.84 (+1.63%)

RCUS Arcus Biosciences
$26.04 /

-1.46 (-5.31%)

QGEN Qiagen
$42.59 /

+0.17 (+0.40%)

PFE Pfizer
$33.43 /

+0.2 (+0.60%)

NVS Novartis
$91.13 /

+1.47 (+1.64%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

ILMN Illumina
$370.43 /

+8.18 (+2.26%)

GSK GlaxoSmithKline
$41.12 /

+0.18 (+0.44%)

GILD Gilead
$77.23 /

+3.18 (+4.29%)

BNTX BioNTech
$51.42 /

+0.48 (+0.94%)

BMY Bristol-Myers
$56.34 /

+0.35 (+0.63%)

AZN AstraZeneca
$53.05 /

+0.39 (+0.74%)

ABBV AbbVie
$96.72 /

+0.45 (+0.47%)

A Agilent
$88.82 /

+0.6 (+0.68%)

Over a month ago
Conference/Events
Novocure management to meet virtually with Mizuho » 04:55
05/21/20
05/21
04:55
05/21/20
04:55
NVCR

Novocure

$63.58 /

+0.73 (+1.16%)

Virtual Meetings to be…

Virtual Meetings to be held May 20-21 hosted by Mizuho.

ShowHide Related Items >><<
NVCR Novocure
$63.58 /

+0.73 (+1.16%)

NVCR Novocure
$63.58 /

+0.73 (+1.16%)

05/20/20 Piper Sandler
Novocure remains top idea in oncology equipment at Piper Sandler
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
NVCR Novocure
$63.58 /

+0.73 (+1.16%)

NVCR Novocure
$63.58 /

+0.73 (+1.16%)

Recommendations
Novocure remains top idea in oncology equipment at Piper Sandler » 05:17
05/20/20
05/20
05:17
05/20/20
05:17
NVCR

Novocure

$62.85 /

-2.4 (-3.68%)

Piper Sandler analyst…

Piper Sandler analyst Jason Bednar says Novocure remains his top idea in oncology equipment after details of the company's TRIDENT study evaluating benefits of concomitant Optune with radiotherapy and temozolomide were made available. Important for investors, the subjects enrolled in both arms of the study will be billable, revenue-generating patients, and therefore shouldn't cannibalize Novocure's existing commercial glioblastoma franchise, Bednar tells investors in a research note. The analyst believes Novocure may be even be able to bill for the additional period of time being studied. He keeps an Overweight rating on the shares with an $85 price target.

ShowHide Related Items >><<
NVCR Novocure
$62.85 /

-2.4 (-3.68%)

NVCR Novocure
$62.85 /

-2.4 (-3.68%)

05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
05/01/20 Oppenheimer
Novocure downgraded to Perform from Outperform at Oppenheimer
NVCR Novocure
$62.85 /

-2.4 (-3.68%)

NVCR Novocure
$62.85 /

-2.4 (-3.68%)

Conference/Events
Novocure management to meet virtually with Mizuho » 04:55
05/20/20
05/20
04:55
05/20/20
04:55
NVCR

Novocure

$62.85 /

-2.4 (-3.68%)

Virtual Meetings to be…

Virtual Meetings to be held May 20-21 hosted by Mizuho.

ShowHide Related Items >><<
NVCR Novocure
$62.85 /

-2.4 (-3.68%)

NVCR Novocure
$62.85 /

-2.4 (-3.68%)

05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
05/01/20 Oppenheimer
Novocure downgraded to Perform from Outperform at Oppenheimer
NVCR Novocure
$62.85 /

-2.4 (-3.68%)

NVCR Novocure
$62.85 /

-2.4 (-3.68%)

Conference/Events
Novocure management to meet virtually with Mizuho » 08:16
05/19/20
05/19
08:16
05/19/20
08:16
NVCR

Novocure

$65.25 /

+0.46 (+0.71%)

Virtual Meetings to be…

Virtual Meetings to be held May 20-21 hosted by Mizuho.

ShowHide Related Items >><<
NVCR Novocure
$65.25 /

+0.46 (+0.71%)

NVCR Novocure
$65.25 /

+0.46 (+0.71%)

05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
05/01/20 Oppenheimer
Novocure downgraded to Perform from Outperform at Oppenheimer
NVCR Novocure
$65.25 /

+0.46 (+0.71%)

NVCR Novocure
$65.25 /

+0.46 (+0.71%)

Recommendations
Piper says Novocure opens up largest GBM market with China approval » 10:52
05/13/20
05/13
10:52
05/13/20
10:52
NVCR

Novocure

$62.40 /

-0.48 (-0.76%)

, ZLAB

Zai Lab

$72.13 /

+2.81 (+4.05%)

After Novocure (NVCR) and…

After Novocure (NVCR) and its partner, Zai Lab (ZLAB), announced China's NMPA approved Optune for the treatment of both newly diagnosed and recurrent glioblastoma, or GBM, patients, Piper Sandler analyst Jason Bednar said the timing was in line with his expectations. The news clears the way for Optune to launch in China, which is the largest GBM market, and good early success in Hong Kong leads him to believe prescriptions could scale nicely over the coming quarters, Bednar tells investors. He keeps an Overweight rating and $85 price target on Novocure shares.

ShowHide Related Items >><<
ZLAB Zai Lab
$72.13 /

+2.81 (+4.05%)

NVCR Novocure
$62.40 /

-0.48 (-0.76%)

NVCR Novocure
$62.40 /

-0.48 (-0.76%)

05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
05/01/20 Oppenheimer
Novocure downgraded to Perform from Outperform at Oppenheimer
04/09/20 Evercore ISI
Novocure downgraded to Underperform from In Line at Evercore ISI
ZLAB Zai Lab
$72.13 /

+2.81 (+4.05%)

05/06/20 H.C. Wainwright
Priority Review in China accelerates revenues for Paratek, says H.C. Wainwright
04/27/20
Zai Lab initiated with a Buy at Goldman Sachs
04/16/20 Guggenheim
Guggenheim starts 'uniquely compelling' Zai Lab at Buy
04/15/20 Guggenheim
Zai Lab initiated with a Buy at Guggenheim
ZLAB Zai Lab
$72.13 /

+2.81 (+4.05%)

NVCR Novocure
$62.40 /

-0.48 (-0.76%)

NVCR Novocure
$62.40 /

-0.48 (-0.76%)

Hot Stocks
Novocure announces China NMPA approval of Optune combination for GBM » 10:15
05/13/20
05/13
10:15
05/13/20
10:15
NVCR

Novocure

$62.00 /

-0.88 (-1.40%)

, ZLAB

Zai Lab

$70.97 /

+1.65 (+2.38%)

Novocure (NVCR) and Zai…

Novocure (NVCR) and Zai Lab Limited (ZLAB) announced that the China National Medical Products Administration, or NMPA, has approved the Marketing Authorization Application for Optune in combination with temozolomide for the treatment of patients with newly diagnosed glioblastoma, or GBM, and also as a monotherapy for the treatment of patients with recurrent GBM. Optune is the first treatment for glioblastoma approved in China in over 15 years, the companies stated.

ShowHide Related Items >><<
ZLAB Zai Lab
$70.97 /

+1.65 (+2.38%)

NVCR Novocure
$62.00 /

-0.88 (-1.40%)

NVCR Novocure
$62.00 /

-0.88 (-1.40%)

05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
05/01/20 Oppenheimer
Novocure downgraded to Perform from Outperform at Oppenheimer
04/09/20 Evercore ISI
Novocure downgraded to Underperform from In Line at Evercore ISI
ZLAB Zai Lab
$70.97 /

+1.65 (+2.38%)

05/06/20 H.C. Wainwright
Priority Review in China accelerates revenues for Paratek, says H.C. Wainwright
04/27/20
Zai Lab initiated with a Buy at Goldman Sachs
04/16/20 Guggenheim
Guggenheim starts 'uniquely compelling' Zai Lab at Buy
04/15/20 Guggenheim
Zai Lab initiated with a Buy at Guggenheim
ZLAB Zai Lab
$70.97 /

+1.65 (+2.38%)

NVCR Novocure
$62.00 /

-0.88 (-1.40%)

NVCR Novocure
$62.00 /

-0.88 (-1.40%)

Hot Stocks
Zai Lab receives China NMPA approval for Optune for glioblastoma » 09:45
05/13/20
05/13
09:45
05/13/20
09:45
ZLAB

Zai Lab

$69.32 /

+ (+0.00%)

, NVCR

Novocure

$62.88 /

+ (+0.00%)

Zai Lab Limited (ZLAB)…

Zai Lab Limited (ZLAB) and Novocure (NVCR) announced that the China National Medical Products Administration has approved the Marketing Authorization Application for Optune in combination with temozolomide for the treatment of patients with newly diagnosed glioblastoma, and also as a monotherapy for the treatment of patients with recurrent GBM. GBM is the most common form of primary brain cancer, and Optune is the first treatment for glioblastoma approved in China in over 15 years.

ShowHide Related Items >><<
ZLAB Zai Lab
$69.32 /

+ (+0.00%)

NVCR Novocure
$62.88 /

+ (+0.00%)

ZLAB Zai Lab
$69.32 /

+ (+0.00%)

05/06/20 H.C. Wainwright
Priority Review in China accelerates revenues for Paratek, says H.C. Wainwright
04/27/20
Zai Lab initiated with a Buy at Goldman Sachs
04/16/20 Guggenheim
Guggenheim starts 'uniquely compelling' Zai Lab at Buy
04/15/20 Guggenheim
Zai Lab initiated with a Buy at Guggenheim
NVCR Novocure
$62.88 /

+ (+0.00%)

05/01/20 SunTrust
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
05/01/20 Oppenheimer
Novocure downgraded to Perform from Outperform at Oppenheimer
04/09/20 Evercore ISI
Novocure downgraded to Underperform from In Line at Evercore ISI
ZLAB Zai Lab
$69.32 /

+ (+0.00%)

NVCR Novocure
$62.88 /

+ (+0.00%)

NVCR Novocure
$62.88 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.